Zydus Lifesciences

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone tablets, 40 mg/12.5 mg and 40 mg/25 mg.

Zydus Lifesciences Ltd.’s shares were up by 2.25 per cent to ₹1,031.95 on the BSE. The company announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets, a generic version of CABOMETYX, intended for the US market.

Paytm’s parent company One97 Communications president and chief operating officer Bhavesh Gupta has resigned from the company, an official statement said. Gupta steered the lending business, online and offline payments, and compliances, at Paytm. Verticals, headed by him were adversely impacted by the RBI’s ban on Paytm Payments Bank (PPBL) from carrying on new transactions.

Apollo HealthCo Limited, a subsidiary of Apollo Hospitals Enterprise Limited, has entered into a binding agreement to raise equity capital of ₹2,475 crore from Advent International, one of the world’s largest and most experienced global private equity investors. In addition, Apollo 24/7 has entered into a framework agreement to integrate 100% of Keimed Private Limited, India’s leading wholesale pharma distributor, in a phased manner over the next 24-30 months.

Apollo HealthCo Limited, a subsidiary of Apollo Hospitals Enterprise Limited, has entered into a binding agreement to raise equity capital of ₹2,475 crore from Advent International, one of the world’s largest and most experienced global private equity investors. In addition, Apollo 24/7 has entered into a framework agreement to integrate 100% of Keimed Private Limited, India’s leading wholesale pharma distributor, in a phased manner over the next 24-30 months.

Apollo HealthCo Limited, a subsidiary of Apollo Hospitals Enterprise Limited, has entered into a binding agreement to raise equity capital of ₹2,475 crore from Advent International, one of the world’s largest and most experienced global private equity investors. In addition, Apollo 24/7 has entered into a framework agreement to integrate 100% of Keimed Private Limited, India’s leading wholesale pharma distributor, in a phased manner over the next 24-30 months.

Apollo HealthCo Limited, a subsidiary of Apollo Hospitals Enterprise Limited, has entered into a binding agreement to raise equity capital of ₹2,475 crore from Advent International, one of the world’s largest and most experienced global private equity investors. In addition, Apollo 24/7 has entered into a framework agreement to integrate 100% of Keimed Private Limited, India’s leading wholesale pharma distributor, in a phased manner over the next 24-30 months.

Apollo HealthCo Limited, a subsidiary of Apollo Hospitals Enterprise Limited, has entered into a binding agreement to raise equity capital of ₹2,475 crore from Advent International, one of the world’s largest and most experienced global private equity investors. In addition, Apollo 24/7 has entered into a framework agreement to integrate 100% of Keimed Private Limited, India’s leading wholesale pharma distributor, in a phased manner over the next 24-30 months.

Apollo HealthCo Limited, a subsidiary of Apollo Hospitals Enterprise Limited, has entered into a binding agreement to raise equity capital of ₹2,475 crore from Advent International, one of the world’s largest and most experienced global private equity investors. In addition, Apollo 24/7 has entered into a framework agreement to integrate 100% of Keimed Private Limited, India’s leading wholesale pharma distributor, in a phased manner over the next 24-30 months.